Miriam Merad's 20-Year Journey Transforms Cancer Immunotherapy

TL;DR
Miriam Merad's 20-year research on macrophages, immune cells involved in inflammation and immune response, is challenging traditional cancer treatments focused on T cells, and early clinical data suggest that targeting macrophages could enhance immunotherapy effectiveness and address aging and autoimmune diseases.
Topics:healthhealth-and-science#aging#autoimmune-disorders#cancer-immunotherapy#clinical-trials#health-and-science#macrophages
Want the full story? Read the original reporting
Read on statnews.com